Last updated: April 25, 2026
What is MYFEMBREE and what is its regulatory status?
MYFEMBREE is a once-daily, oral, combination therapy consisting of relugolix (GnRH receptor antagonist) + estradiol (E2) + norethindrone acetate (NETA), indicated for:
- Moderate to severe pain associated with endometriosis
- Heavy menstrual bleeding (HMB) associated with uterine fibroids (in premenopausal women)
Core clinical-development identifiers
- Relugolix + E2/NETA regimen is the same platform used across the endometriosis and uterine fibroids programs.
- The endometriosis program includes pivotal phase 3 studies SPIRIT 1 and SPIRIT 2 (relugolix-based regimen in the E2/NETA add-back approach).
- The uterine fibroids program includes pivotal phase 3 studies LIBERTY 1 and LIBERTY 2.
FDA-approved positioning (labels)
- MYFEMBREE carries an FDA boxed warning for increased risk of loss of pregnancy and thromboembolic events and includes safety limitations consistent with estradiol/progestin-containing hormonal therapy.
What does the latest clinical trials landscape show?
As of the most recently available public sources that report updated trial outcomes and regulatory updates for this product, the clinical picture is dominated by:
- Pivotal phase 3 outcomes (already established)
- Post-approval lifecycle activity concentrated on label expansion, real-world evidence publication, and longer-term safety/clinical practice assessments
No new pivotal phase 3 readout sequence that would materially change the efficacy or safety profile has been identified in the standard public trial registry and conference literature set tied to MYFEMBREE since the initial approvals, based on accessible public documentation. The practical implication is that market underwriting continues to rely on the established SPIRIT (endometriosis) and LIBERTY (fibroids) efficacy endpoints, plus safety and discontinuation dynamics already observed in the pivotal dataset.
Key efficacy anchors used for commercial underwriting
| Indication |
Pivotal program |
Primary clinical endpoints used for commercialization |
| Endometriosis pain |
SPIRIT 1, SPIRIT 2 |
Reduction in endometriosis-associated pain measured via validated symptom instruments (trial-specific composite pain measures) with additional findings on disease-associated symptom burden |
| Uterine fibroids (HMB) |
LIBERTY 1, LIBERTY 2 |
Menstrual blood loss response and improvement in bleeding-related outcomes, typically including responder rates and durability across treatment weeks |
(Trial-specific numerical results are reported in FDA review materials and sponsor publications and are the basis for label endpoints and payer assessment; see cited FDA and sponsor sources.)
What is the competitive market context for endometriosis and uterine fibroids?
MYFEMBREE competes in two overlapping hormonal treatment markets with different payer thresholds.
Endometriosis pain
Main alternatives include:
- Oral progestins and combined hormonal contraception
- GnRH agonists (e.g., leuprolide-based regimens) with add-back therapy
- Other GnRH antagonists or targeted agents where available
Commercial differentiators MYFEMBREE buyers evaluate:
- Oral once-daily dosing
- Magnitude and speed of pain relief relative to comparators in the pivotal trial dataset
- Safety and tolerability versus GnRH agonist class effects
Uterine fibroids (heavy menstrual bleeding)
Main alternatives include:
- Levonorgestrel IUD
- Tranexamic acid
- Oral hormonal options
- GnRH agonists and antagonists in appropriate settings
- Procedural and surgical options (myomectomy, hysterectomy) in later lines
Commercial differentiators:
- Bleeding control response rate and durability
- Avoidance of procedures for a subset of patients
- Hormonal side-effect profile, including bone and vasomotor-related tolerability considerations
Clinical takeaways used by payers and formularies
Payer decisioning for MYFEMBREE typically focuses on:
- Clinical endpoint performance from SPIRIT and LIBERTY
- Tolerability and discontinuation risk
- Eligibility alignment with label indications, prior therapy steps, and contraindication exclusions
- Cost-effectiveness versus alternatives for symptom and bleeding control
How big are the addressable markets and what assumptions drive projections?
A practical market model for MYFEMBREE in 2025 to 2030 depends on:
- Patient prevalence for symptomatic endometriosis and clinically significant heavy menstrual bleeding from fibroids
- Treatment-seeking rates (diagnosis-to-treatment conversion)
- Formulary access and utilization after payer restrictions
- Line-of-therapy adoption (how early in the pathway the drug gains use)
- Switch and persistence (especially in pain management and bleeding control settings)
Public market sizing for endometriosis and uterine fibroids is broad; the underwriting therefore commonly uses:
- Prevalence of disease and symptomatic subsets
- Proportion receiving hormonal pharmacotherapy
- Proportion willing or able to use GnRH-based oral agents
- Penetration of MYFEMBREE at formulary-access points
Market projection: where MYFEMBREE is likely to land
MYFEMBREE’s growth profile in commercial planning is driven by two linked adoption arcs:
- Endometriosis pain uptake among patients who need oral options with GnRH-based control
- Uterine fibroids HMB uptake where payers accept GnRH-based therapies for bleeding control and where procedural deferral is valued
Projection framework (how to model MYFEMBREE)
A robust projection model for business use typically separates the market into:
- Commercial demand (new starts)
- Treatment continuation (persistence)
- Switching (patients moving from other medical therapies)
Commercial sensitivity drivers:
- Formulary tiering and prior authorization behavior
- Net price and rebates
- Safety communications and discontinuation rates
- Competition response (other oral hormonal/gonadotropin pathway products)
What is the current commercial read-through from approvals and label fit?
MYFEMBREE’s label fit is narrow enough to create payer selectivity but broad enough for meaningful uptake in:
- Premenopausal women with symptomatic endometriosis
- Premenopausal women with HMB associated with uterine fibroids
This dual-indication structure is strategically relevant because it increases the number of payer channels and clinician communities involved (gynecology pain management plus fibroid care).
Business risk and upside: patent, lifecycle, and payer posture
Patent and exclusivity posture (commercial impact)
MYFEMBREE is a branded combination product; protection strategy typically relies on:
- Composition and formulation patents
- Method-of-use protection for endometriosis and fibroids indications
- Regulatory exclusivity where applicable (periods depend on the specific submission pathway)
The practical impact on projections:
- Near-term pricing power depends on how many legally actionable patents remain and whether challengers succeed
- Generic/biosimilar displacement risk depends on expiration timing and any allowed “design-around” combination entry that retains clinical equivalence
(For formal patent-to-expiry mapping, the analysis must tie to the specific Orange Book entries; see the cited FDA sources below.)
Lifecycle levers
Common lifecycle levers for this platform include:
- Label refinements
- Expanded patient subgroups
- Additional evidence generation to support payer acceptance
Projected market outcomes (2018 baseline to 2030 planning horizon)
No single public dataset in the cited sources here provides a complete, regulator-verified sales time series and consensus 2030 forecast. Underwriting therefore relies on:
- endpoint-backed clinical value
- payer access assumptions
- competitive adoption dynamics
Commercial scenario bands for planning
For high-stakes budgeting, the planning approach uses three adoption scenarios:
- Base case: continued gradual expansion with payer-controlled volume and stable persistence
- Upside case: faster formulary access and higher early-line uptake driven by favorable tolerability and clinical impact
- Downside case: restrictive prior authorization plus strong competitor displacement in fibroid and endometriosis pathways
Key Takeaways
- MYFEMBREE is an oral, once-daily relugolix + E2 + NETA regimen positioned for endometriosis-associated pain and heavy menstrual bleeding due to uterine fibroids.
- The clinical evidence base that underwrites commercialization is anchored in SPIRIT (endometriosis) and LIBERTY (fibroids) pivotal phase 3 programs reported in public FDA and sponsor materials.
- Current public trial updates reflect continued post-approval activity rather than a new pivotal phase 3 outcome that changes the efficacy or safety foundation used for market decisions.
- Market projections should be modeled using a two-indication framework with separate adoption and persistence dynamics, under constrained payer behavior and competitive response.
- Commercial risk and upside hinge on formulary access, persistence/discontinuation, net price, and the durability of patent protection mapped through FDA listing data.
FAQs
-
What makes MYFEMBREE distinct versus GnRH agonists in payer and clinician decisioning?
Its oral once-daily GnRH antagonist mechanism with an estradiol/norethindrone acetate add-back approach is positioned to balance symptom control with tolerability.
-
Which trials anchor MYFEMBREE’s efficacy for endometriosis and fibroids?
Endometriosis pain is anchored in SPIRIT 1 and SPIRIT 2; heavy menstrual bleeding from fibroids is anchored in LIBERTY 1 and LIBERTY 2.
-
Are there new pivotal phase 3 outcomes published in standard public sources that would reset the commercial view?
Based on publicly available updates in the cited set, the primary commercial view remains anchored in the established pivotal programs; no newly reported pivotal readout that changes underwriting is present in these sources.
-
How should a market model split MYFEMBREE demand?
Separate into endometriosis starts/persistence and uterine fibroids starts/persistence, then apply formulary access and prior authorization constraints to net-access volumes.
-
What commercial factors most influence adoption for MYFEMBREE?
Formulary tiering, prior authorization, net pricing and rebates, persistence/discontinuation, and competitive displacement in each indication.
References (APA)
- U.S. Food and Drug Administration. (n.d.). FDA label: MYFEMBREE (relugolix, estradiol, and norethindrone acetate). https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: MYFEMBREE. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Orange Book: MYFEMBREE (relugolix, estradiol, and norethindrone acetate). https://www.accessdata.fda.gov/scripts/cder/ob/
